Henoch-Schönlein Purpura with Adalimumab Therapy for Ulcerative Colitis: A Case Report and Review of the Literature
Tumor necrosis factor-α (TNFα) inhibitor therapy has signified an important milestone in the fight against many rheumatological disorders and inflammatory bowel disease (IBD). Cutaneous adverse events caused by this class of medications are well known but relatively uncommon. Most reactions are mild...
Saved in:
Main Authors: | Joseph J. LaConti, Jean A. Donet, Jeong Hee Cho-Vega, Daniel A. Sussman, Dana Ascherman, Amar R. Deshpande |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-01-01
|
Series: | Case Reports in Rheumatology |
Online Access: | http://dx.doi.org/10.1155/2016/2812980 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Gut Microbiota Variations between Henoch-Schonlein Purpura and Henoch-Schonlein Purpura Nephritis
by: Fang Zhou, et al.
Published: (2022-01-01) -
The influence of respiratory infections on Henoch-Schönlein purpura in children
by: Bili Wang, et al.
Published: (2025-01-01) -
Henoch-Schonlein Purpura—A Case Report and Review of the Literature
by: Amit B. Sohagia, et al.
Published: (2010-01-01) -
Henoch–Schönlein Purpura (IgA Vasculitis) in Association with Thyrotoxicosis
by: Mojgan Sanjari, et al.
Published: (2021-01-01) -
Therapy for Children with Henoch-Schonlein Purpura Nephritis: A Systematic Review
by: Marco Zaffanello, et al.
Published: (2007-01-01)